Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion-Reference-Cited by-同舟云学术

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

Published:2015-04-20 Issue:5 Volume:21 Page:512-517
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Bonner Caroline,Kerr-Conte Julie,Gmyr Valéry,Queniat Gurvan,Moerman Ericka,Thévenet Julien,Beaucamps Cédric,Delalleau Nathalie,Popescu Iuliana,Malaisse Willy J,Sener Abdullah,Deprez Benoit,Abderrahmani Amar,Staels Bart,Pattou François

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.3828.pdf

Reference50 articles.

1. Kahn, S.E., Cooper, M.E. & Del Prato, S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383, 1068–1083 (2014).

2. Demaris, K.M. & White, J.R. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 49, 289–301 (2013).

3. Jabbour, S.A. & Goldstein, B.J. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 62, 1279–1284 (2008).

4. Komoroski, B. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513–519 (2009).

5. Nair, S. & Wilding, J.P. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 34–42 (2010).

Cited by 547 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From sugar binders to diabetes fighters: the lectin saga of antihyperglycemic activity through systematic review and meta-analysis;Frontiers in Pharmacology;2024-09-11

2. Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care;Biomedicines;2024-09-07

3. SGLT-2i associated diabetic ketoacidosis in the setting of cardiogenic shock;BMJ Case Reports;2024-09

4. Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction;Circulation Research;2024-08-16

5. Evaluating the potential impact of sodium–glucose cotransporter‐2 inhibitor “canagliflozin” on the hepatic damage triggered by hypertension in rats;Microscopy Research and Technique;2024-07-25